337,338,339 GLP-1 can exert its anti-inflammatory effects by activating its receptor, GLP-1R

These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk

These warning signs can also apply to brick-and-mortar locations, such as a wellness center or medical spa
A 2025 Kinsey Institute survey revealed that more than half of GLP-1 users said the drugs had changed their sex and dating livessometimes for the worse
The percentage of participants who discontinued the medication due to AE ranged between 20 and 29%
Make sure your care provider is aware of your medical history and any other drugs you may be taking